Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire | Orphanet Journal of Rare Diseases | Full Text

Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire | Orphanet Journal of Rare Diseases | Full Text

Orphanet Journal of Rare Diseases

Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire

• Esther Noël, 
• Bertrand Dussol, 
• Didier Lacombe, 
• Najya Bedreddine, 
• Alain Fouilhoux, 
• Pierre Ronco, 
• Delphine Genevaz, 
• Soumeya Bekri, 
• Albert Hagège, 
• Frédérique Dupuis-Siméon, 
• Valérie Derrien Ansquer, 
• Dominique P. Germain & 
• Olivier Lidove 

Orphanet Journal of Rare Diseases volume 14, Article number: 284 (2019) Cite this article

Article metrics

• 90 Accesses

Abstract

Background

Fabry disease (FD) is a rare, X-linked, inherited lysosomal disease caused by absent or reduced α-galactosidase A activity. Due to the heterogeneity of disease presentation and progression, generic patient-reported outcome (PRO) tools do not provide accurate insight into patients’ daily lives and impact of disease specific treatments. Also, the French National Health Authority, (HAS) actively encourages a patient-centric approach to improve the quality of care throughout the patient journey. In response to this initiative, we aimed to develop and validate a specific, self-reported, Patient Needs Questionnaire for people living with Fabry disease to appraise patient needs and expectations towards their treatment (PNQ Fabry). This endeavour was led with the help of French patient associations (APMF & VML) and dedicated expert centres. PNQ Fabry was developed according to the FDA/EMA methodologies and best practices for the development of PRO tools in rare diseases. Our approach comprised of three steps, as follows: concept elicitation and item generation, item reduction, and final validation of the questionnaire through a two-stage survey.

Results

Intrinsic and extrinsic reliability was established, using a validated benchmark questionnaire. With the invaluable help of patient associations, we recruited a satisfactory population in this rare disease setting, to ensure robust participation to validate our PNQ (final number of questionnaires: 76). At the end of the process, a 26-item patient-reported questionnaire was obtained with excellent psychometric properties, exhibiting very satisfactory measurement outcomes for reliability and validity. The results of this initiative demonstrate that the PNQ Fabry is accurate, suitable and tailored to FD patients, as it addresses themes identified during patient interviews, that were further validated through statistical analyses of quantitative surveys. An ongoing phase IV study is using this tool.

Conclusion

We believe the PNQ Fabry will be a reliable and insightful tool in clinical practice, to improve patient management in FD.